About VYEPTI CONNECT

VYEPTI CONNECT offers eligible patients access support throughout their treatment with VYEPTI. Providers can enroll their patients so they may take advantage of the program's helpful offerings.

You can enroll your patients in VYEPTI CONNECT by:

Fax icon

Faxing an enrollment form to
866-868-7071

Call icon

Calling 833-4-VYEPTI,
option 1

Mail icon

Mailing an enrollment form to:
2250 Perimeter Park Suite 300
Morrisville, NC 27560

The VYEPTI CONNECT team is here to answer your access and reimbursement questions

Access and reimbursement support is provided by a team of reimbursement specialists.

VYEPTI Connect Liaison icon

VYEPTI CONNECT Liaisons

When you enroll your patients in VYEPTI CONNECT, you have access to a liaison who can assist with any of the VYEPTI CONNECT informational offerings.* Liaisons can be contacted by phone at 833-4-VYEPTI, option 1, Monday through Friday, 8 am-8 pm (ET).

 

Field Reimbursement Specialists

Access questions can also be directed to a Field Reimbursement Specialist (FRS) who can help in person, virtually, or by phone.

Field Reimbursement Specialist icon
PDF icon

VYEPTI Permanent J-code (J3032)

The Centers for Medicare and Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) has assigned VYEPTI® (eptinezumab-jjmr) a permanent HCPCS J-code: J3032. Learn more here.

Providing VYEPTI patients with access support

*VYEPTI CONNECT is only available for patients who have been prescribed VYEPTI and are enrolled in VYEPTI CONNECT; support may vary based on patient eligibility. Click here for full Terms and Conditions for VYEPTI CONNECT.

Benefits investigation icon

Benefits investigation

Benefits investigation informational support includes gathering medical coverage requirements, assignment of benefits, and, if applicable, infusion location requirements of the payer for VYEPTI.

Prior authorization (PA)/medical exception icon

Prior authorization (PA)/medical exception

PA/medical exception support provides information on the payer’s process for determining VYEPTI coverage, including blank PA forms that can be submitted to request patient access to VYEPTI. Once a PA is submitted, VYEPTI CONNECT can confirm the patient’s final coverage information for VYEPTI.

Appeals support icon

Appeals support

Appeals support offers information on the payer’s process if an HCP wants to appeal a denial or other decision regarding VYEPTI coverage. If an appeal is submitted, VYEPTI CONNECT can confirm the patient’s final coverage information for VYEPTI.

Infusion locations search icon

Infusion locations

Infusion locations can be provided by VYEPTI CONNECT for patients who need to infuse at a location other than their prescriber’s office or clinic. VYEPTI CONNECT can check the patient's insurance to confirm that the infusion locations are in their network. You can search directly for alternate infusion sites in your area here.

Prescription coordination icon

Prescription coordination

For offices that do not administer VYEPTI, VYEPTI CONNECT can send the VYEPTI prescription to an infusion location or in-network specialty pharmacy.

Clock icon

Infusion reminders

Infusion reminders can alert healthcare providers about their eligible patients’ upcoming VYEPTI infusions.

Financial assistance icon

Financial assistance

Financial assistance is available for eligible commercially insured patients through the VYEPTI CONNECT Copay Assistance Program. Eligible commercially insured patients may pay as little as $5 per infusion every 3 months for VYEPTI. A maximum annual benefit limit of $4000 and other restrictions may apply. Patients can check eligibility requirements and enroll in the program by calling 833-4-VYEPTI, option 3, or learn more here. Terms and conditions apply.

VYEPTI GO logo

Nursing support

Ongoing support from registered nurses is available for patients through VYEPTI GO. This support program provides information to patients on preparing for their infusions, answers questions about VYEPTI and migraine, and can direct them to helpful resources. Patients can learn more and enroll in the program by calling 833-4-VYEPTI, option 2, or learn more here.

Resources PDF icon

Access and support resources

Enrollment form, sample letters of medical necessity and appeal, a PA checklist, VYEPTI CONNECT Copay Assistance Program information, and more tools and downloads are at your fingertips.

†Patients are not eligible for financial assistance if they are uninsured or if their prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare programs, including but not limited to Medicare or Medicaid, United States Department of Veterans Administration, US Department of Defense, or TRICARE. The VYEPTI CONNECT Copay Assistance Program covers the cost of VYEPTI only. Administration and other fees are not covered by this copay program. Patients must be US residents age 17 years or older and have a valid VYEPTI prescription. Click here for full Terms and Conditions for the VYEPTI CONNECT Copay Assistance Program.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.